Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK


CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) announced a recent publication in Expert Review of Neurotherapeutics titled “A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain by Eugene R. Viscusi, M.D., Director of Acute Pain Management at Jefferson Health (DOI:

“I am pleased to include this additional publication supporting OLINVYK’s clinical development program highlighting the efficacy and safety endpoints utilized in the clinical studies of more than 1,500 patients with moderate-to-severe acute pain,” said Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena. “We believe Dr. Viscusi’s review highlights the strength of the evidence base for the safety and efficacy of OLINVYK, and also elucidates the practical clinical importance of the responder rate used as the primary outcome measure in the OLINVYK pivotal Phase 3 APOLLO trials.”

READ:  Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel

The publication can be found at

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.